Abstract
An intracellular hallmark of Alzheimer’s Disease (AD) is accumulation of hyperphosphorylated tau as paired helical filaments (PHF). A significant advance in understanding the behavior of tau occurred when it was reported that VQIVYK hexapeptide motif is responsible for initiating the process of aggregation. In the last years, a great number of Tau aggregation inhibitors have been developed, including flavonoids. However, the binding mode of these potential drugs is not well established. In this work, the behavior and conformational stability of the Tau hexapeptide306VQIVYK311 were investigated in the presence of two known flavonoid inhibitors using Molecular Interaction Fields (MIFs), pharmacophore perception and molecular dynamics (MD) simulations. We have also proposed a likely binding mode for such inhibitors with the hexapeptide, which agrees with experimental data and is able to explain structure-activity relationships between different flavonoids.
Keywords: Alzheimer’s disease, tau protein, flavonoids, molecular interaction fields, pharmacophore perception, molecular dynamics simulations
Current Bioactive Compounds
Title:In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Volume: 9 Issue: 1
Author(s): Susimaire Pedersoli-Mantoani, Carlos Henrique Tomich de Paula da Silva and Vinicius Barreto da Silva
Affiliation:
Keywords: Alzheimer’s disease, tau protein, flavonoids, molecular interaction fields, pharmacophore perception, molecular dynamics simulations
Abstract: An intracellular hallmark of Alzheimer’s Disease (AD) is accumulation of hyperphosphorylated tau as paired helical filaments (PHF). A significant advance in understanding the behavior of tau occurred when it was reported that VQIVYK hexapeptide motif is responsible for initiating the process of aggregation. In the last years, a great number of Tau aggregation inhibitors have been developed, including flavonoids. However, the binding mode of these potential drugs is not well established. In this work, the behavior and conformational stability of the Tau hexapeptide306VQIVYK311 were investigated in the presence of two known flavonoid inhibitors using Molecular Interaction Fields (MIFs), pharmacophore perception and molecular dynamics (MD) simulations. We have also proposed a likely binding mode for such inhibitors with the hexapeptide, which agrees with experimental data and is able to explain structure-activity relationships between different flavonoids.
Export Options
About this article
Cite this article as:
Pedersoli-Mantoani Susimaire, Henrique Tomich de Paula da Silva Carlos and Barreto da Silva Vinicius, In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease, Current Bioactive Compounds 2013; 9 (1) . https://dx.doi.org/10.2174/1573407211309010004
DOI https://dx.doi.org/10.2174/1573407211309010004 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neural Stem Cells Transplanted in a Mouse Model of Parkinson’s Disease Differentiate to Neuronal Phenotypes and Reduce Rotational Deficit
CNS & Neurological Disorders - Drug Targets Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: QSAR Models for Computer-Aided Drug Design and Molecular Docking for Disorders of the Central Nervous System and Other Diseases]
Current Topics in Medicinal Chemistry Investigations on the Structural Characteristics that Seed the Aggregation of Amyloid-β<sub>1-42</sub> Peptide: Insights from Molecular Dynamics Simulations
Current Proteomics Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry A Genetic Dissection of Antipsychotic Induced Movement Disorders
Current Medicinal Chemistry The Putative Impact of Metabolic Health on Default Mode Network Activity and Functional Connectivity in Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Delirium in Older Patients – A Review
Current Psychiatry Reviews Cardiovascular Complications in Patients with Klinefelter’s Syndrome
Current Pharmaceutical Design Effects of Physical Exercise on Inflammatory Markers of Atherosclerosis
Current Pharmaceutical Design Molecular Mechanisms of Ischemic Neuronal Cell Death - With Relevance to Alzheimers Disease
Current Alzheimer Research From Pharmacotherapy to Pathophysiology: Emerging Mechanisms of Apolipoprotein D in Psychiatric Disorders
Current Molecular Medicine Treatment and Prevention of Alcohol Hangover
Current Drug Abuse Reviews Alzheimer’s Disease-related Biomarkers in Aging Adults with Down Syndrome: Systematic Review
Current Psychiatry Research and Reviews CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease
Current Drug Targets The Role of Aβ Peptides in Alzheimers Disease
Protein & Peptide Letters Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Behcets Syndrome: Literature Review
Current Rheumatology Reviews